MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. Nat. Med. 2023, 29, 115–126

Jiri Neuzil; Jakub Rohlena; Lukas Werner; Zuzana Bielcikova

doi:10.3390/cancers15184476

Cancers (Sep 2023)

MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. Nat. Med. 2023, 29, 115–126

Jiri Neuzil,
Jakub Rohlena,
Lukas Werner,
Zuzana Bielcikova

Affiliations

Jiri Neuzil: School of Pharmacy and Medical Science, Griffith University, Southport, Qld 4222, Australia
Jakub Rohlena: Institute of Biotechnology, Czech Academy of Sciences, 252 50 Prague, Czech Republic
Lukas Werner: Institute of Biotechnology, Czech Academy of Sciences, 252 50 Prague, Czech Republic
Zuzana Bielcikova: First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic

DOI: https://doi.org/10.3390/cancers15184476
Journal volume & issue: Vol. 15, no. 18
p. 4476

Abstract

Read online

A recent paper published in Nature Medicine reported on the Phase I clinical trial of a mitochondria-targeting anti-cancer agent IACS-01059 in patients with acute myeloid leukemia (AML) and solid tumors [...]

n/a

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords